BioCryst Pharmaceuticals
BCRX
7.22
-0.10
-1.37%
BioCryst Pharmaceuticals
US · BCRX
#2766 by market cap
Listed 1970
7.22
-0.10
-1.37%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.6 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 104.07% -0.56pp
- Institutions
- 378 -2
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund55.07%
Hedge Fund21.78%
VC/PE Fund17.08%
Public Company5.52%
Private Company2.31%
Government Pension Fund1.16%
Insurance Company0.93%
Individual/Insider0.89%
Family Office/Trust0.18%
Top holders as of 2026-09-30
BlackRock
9.46% · 24.33M sh
RA Capital Management, L.P.
6.15% · 15.83M sh
Deerfield Management Company, L.P.
5.87% · 15.10M sh
State Street Global Advisors
4.78% · 12.29M sh
Vanguard Capital Management, LLC
4.38% · 11.27M sh
TCG Crossover Management, LLC
4.28% · 11.02M sh
Vanguard Portfolio Management, LLC
4.09% · 10.53M sh
Perceptive Advisors LLC
4.01% · 10.31M sh
Janus Henderson Group plc
3.71% · 9.54M sh
Vestal Point Capital, LP
3.23% · 8.30M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 9 sells
| Name | Role | Stake |
|---|---|---|
| Jon Stonehouse | Director | 0.40% |
| Charles Gayer | Chief Executive Officer | 0.14% |
| Anthony Doyle | Former Chief Financial Officer | 0.08% |
| Helen Thackray | Former Chief Research & Development Officer | 0.06% |
| Alane Barnes | Chief Legal Officer | 0.06% |
| Vincent Milano | Independent Chairperson | 0.04% |
| Steven K. Galson | Independent Director | 0.02% |
| Theresa Heggie | Independent Director | 0.02% |
| Alan Levin | Independent Director | 0.02% |
| Ronald Dullinger | Chief Commercial Officer | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-30 | Vincent Milano | Independent Chairperson | Other Acquisition | +1,159 | $9.70 |
| 2026-08-30 | Steve Frank | Independent Director | Other Acquisition | +1,288 | $9.70 |
| 2026-08-30 | Jill Milne | Independent Director | Other Acquisition | +1,288 | $9.70 |
| 2026-08-30 | Jon Stonehouse | Director | Other Acquisition | +644 | $9.70 |
| 2026-08-30 | Amy McKee | Independent Director | Other Acquisition | +644 | $9.70 |
| 2026-06-10 | Vincent Milano | Independent Chairperson | Other Acquisition | +15,294 | -- |
| 2026-06-10 | Vincent Milano | Independent Chairperson | Other Derivative Acquisition | +33,540 | $8.50 |
| 2026-06-10 | Alan Levin | Independent Director | Other Acquisition | +15,294 | -- |
| 2026-06-10 | Alan Levin | Independent Director | Other Derivative Acquisition | +33,540 | $8.50 |
| 2026-06-10 | Steve Frank | Independent Director | Other Acquisition | +15,294 | -- |
| 2026-06-10 | Steve Frank | Independent Director | Other Derivative Acquisition | +33,540 | $8.50 |
| 2026-06-10 | Jill Milne | Independent Director | Other Acquisition | +15,294 | -- |
| 2026-06-10 | Jill Milne | Independent Director | Other Derivative Acquisition | +33,540 | $8.50 |
| 2026-06-10 | Theresa Heggie | Independent Director | Other Acquisition | +15,294 | -- |
| 2026-06-10 | Theresa Heggie | Independent Director | Other Derivative Acquisition | +33,540 | $8.50 |
| 2026-06-10 | Jon Stonehouse | Director | Other Acquisition | +15,294 | -- |
| 2026-06-10 | Jon Stonehouse | Director | Other Derivative Acquisition | +33,540 | $8.50 |
| 2026-06-10 | Steven K. Galson | Independent Director | Other Acquisition | +15,294 | -- |
| 2026-06-10 | Steven K. Galson | Independent Director | Other Derivative Acquisition | +33,540 | $8.50 |
| 2026-06-10 | A. Sanders | Independent Director | Other Acquisition | +15,294 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.
BioCryst Pharmaceuticals discussion 0 comments